Chin Keat Chyuan
President & Managing Director
Malaysian, Aged 49
Date of Appointment: 1 September 2023
ACADEMIC/PROFESSIONAL QUALIFICATIONS/MEMBERSHIP(S):
- Executive Education Program, Advanced Strategic Management from IMD Business School
- Master of Business Administration (Merit), General from University of Nottingham - Nottingham University Business School, UK
- Bachelor of Biochemistry (Hons) from National University of Malaysia (UKM), Malaysia
- President of Pharmaceutical Association of Malaysia (PhAMA), an NGO representing 41 international biopharmaceutical companies, focusing on advocacy, industry support, partnerships, and capacity building to enhance healthcare in Malaysia.
- Board of Governor of the American Malaysian Chamber of Commerce (AMCHAM), an international, non-profit, private-sector business association.
PRESENT DIRECTORSHIP(S):
- LISTED ENTITY
- Nil
- OTHER COMPANIES
- Nil
WORKING EXPERIENCE:
With an impressive career spanning over 25 years at Johnson & Johnson (J&J), Chin Keat Chyuan's journey began as a Product Specialist in Medical Devices which swiftly evolved into more pivotal roles. As the Country Director for J&J Malaysia, he oversaw the Ethicon Endo-Surgery business across Southeast Asia from 2010 to 2014. Demonstrating remarkable success, he advanced to become the Managing Director for ONE J&J Malaysia, overseeing the entire organisational business.
In September 2023, Chin was appointed as the President and Managing Director of KPJ Healthcare Berhad. Chin's appointment aligns with KPJ Healthcare’s pursuit of redefining healthcare services through innovation and quality enhancement. His extensive industry experience and proven leadership position him perfectly to lead KPJ Healthcare’s transformative journey. Notably, his strategic expertise has facilitated remarkable market share gains and turnarounds across sectors including hospitals, consumer products, and vision care.
Chin’s leadership extends beyond J&J, as he concurrently serves as the President of the Pharmaceutical Association of Malaysia (PhAMA) and holds a seat on the Board of Governors for the American Malaysian Chamber of Commerce (AMCHAM). He is widely recognised as a thought leader in the industry, actively participating in forums and discussions centred around intellectual property, healthcare access, and corporate responsibilities in line with the United Nations’ Sustainable Development Goals 2030.